Stock 301075 TIBET DUO RUI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tibet Duo Rui Pharmaceutical Co., Ltd.

Equities

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
18.49 CNY -1.96% Intraday chart for Tibet Duo Rui Pharmaceutical Co., Ltd. -4.15% -30.67%
May. 24 Tibet Duo Rui Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 31 May 2024 CI
May. 07 Tranche Update on Tibet Duo Rui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 5, 2024. CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 3,113 2,587 2,134
Enterprise Value (EV) 1 2,522 2,183 1,831
P/E ratio 37.1 x 124 x 111 x
Yield 1.61% - 0.47%
Capitalization / Revenue 5.88 x 6.45 x 6.38 x
EV / Revenue 4.76 x 5.44 x 5.48 x
EV / EBITDA 33.2 x 133 x 105 x
EV / FCF 214,458,969 x -58,699,312 x -228,053,697 x
FCF Yield 0% -0% -0%
Price to Book 3.93 x 3.44 x 2.76 x
Nbr of stocks (in thousands) 80,000 80,000 80,000
Reference price 2 38.91 32.34 26.67
Announcement Date 3/24/22 4/24/23 4/17/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 348.8 449.4 490.2 529.6 401 334.3
EBITDA 1 59.14 68.27 77.94 76.06 16.37 17.37
EBIT 1 53.07 58.51 65.81 62.38 1.812 -0.7458
Operating Margin 15.21% 13.02% 13.43% 11.78% 0.45% -0.22%
Earnings before Tax (EBT) 1 52.03 80.46 101 73.28 21.02 22.25
Net income 1 43.33 71.71 91.99 68.51 20.5 18.85
Net margin 12.42% 15.95% 18.77% 12.94% 5.11% 5.64%
EPS - - 1.530 1.050 0.2600 0.2400
Free Cash Flow - -16.18 -42.59 11.76 -37.18 -8.028
FCF margin - -3.6% -8.69% 2.22% -9.27% -2.4%
FCF Conversion (EBITDA) - - - 15.46% - -
FCF Conversion (Net income) - - - 17.17% - -
Dividend per Share - - - 0.6250 - 0.1250
Announcement Date 3/4/21 3/4/21 3/4/21 3/24/22 4/24/23 4/17/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 38.9 60.5 69.4 590 405 303
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -16.2 -42.6 11.8 -37.2 -8.03
ROE (net income / shareholders' equity) - 63.3% 45.9% 12.8% 2.41% 2.17%
ROA (Net income/ Total Assets) - 13.8% 12.4% 6.38% 0.13% -0.05%
Assets 1 - 518.6 743.9 1,074 15,844 -39,938
Book Value Per Share - - 4.040 9.910 9.390 9.650
Cash Flow per Share - - 1.740 7.640 5.320 5.070
Capex 1 15.1 12.7 50.8 5.35 32.7 23.7
Capex / Sales 4.32% 2.82% 10.37% 1.01% 8.16% 7.09%
Announcement Date 3/4/21 3/4/21 3/4/21 3/24/22 4/24/23 4/17/24
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIBET DUO RUI PHARMACEUTICAL CO., LTD. Stock Tibet Duo Rui Pharmaceutical Co., Ltd.
-30.67% 202M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 238B
NOVARTIS AG Stock Novartis AG
+7.35% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301075 Stock
  4. Financials Tibet Duo Rui Pharmaceutical Co., Ltd.